<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id>
<journal-id journal-id-type="hwp">nng</journal-id>
<journal-id journal-id-type="publisher-id">NNG</journal-id>
<journal-title-group>
<journal-title>Neurology: Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-7839</issn>
<publisher>
<publisher-name>Wolters Kluwer</publisher-name>
<publisher-loc>Baltimore</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27123477</article-id>
<article-id pub-id-type="pmc">4830196</article-id>
<article-id pub-id-type="publisher-id">NG2015001511</article-id>
<article-id pub-id-type="doi">10.1212/NXG.0000000000000058</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>95</subject>
<subject>120</subject>
<subject>155</subject>
<subject>228</subject>
<subject>229</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Clinical/Scientific Notes</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Reversible white matter lesions associated with mutant <italic>EHMT1</italic> and Kleefstra syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Xu</given-names>
</name>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Caluseriu</surname>
<given-names>Oana</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Srivastava</surname>
<given-names>Ratika</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Denny</surname>
<given-names>Anne Marie</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Bolduc</surname>
<given-names>Francois V.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the Department of Pediatrics (X.H., R.S., A.M.D., F.V.B.), Neuroscience and Mental Health Institute (F.V.B.), and Department of Medical Genetics (O.C., F.V.B.), University of Alberta, Edmonton, Alberta, Canada.</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Correspondence to Dr. Bolduc: <email>fbolduc@ualberta.ca</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>22</day>
<month>3</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>2</volume>
<issue>2</issue>
<elocation-id>e58</elocation-id>
<history>
<date date-type="received">
<day>5</day>
<month>11</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>1</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 American Academy of Neurology</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p>
</license>
</permissions>
<self-uri xlink:href="NG2015001511.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body><p>Kleefstra syndrome (KS; OMIM #610253), formerly known as the 9q subtelomeric deletion syndrome, is an autosomal dominant cause of intellectual disability (ID) characterized by hypotonia and facial dysmorphisms.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref></sup> The cause of KS is attributed to haploinsufficiency of the euchromatin histone methyltransferase 1 (<italic>EHMT1</italic>) gene (OMIM *607001) located at chromosome 9q34.3 (i.e., distal long arm of chromosome 9), either by microdeletion or point mutation. <italic>EHMT1</italic> encodes a histone H3 methyltransferase at position Lys-9 (H3K9).<sup><xref ref-type="bibr" rid="R1">1</xref><xref ref-type="bibr" rid="R2">–</xref><xref ref-type="bibr" rid="R3">3</xref></sup></p><p><italic>EHMT</italic>s (including <italic>EHMT1</italic>) form an evolutionarily conserved family that regulates neuronal activity via histone methylation and chromatin modification resulting in transcriptional control.<sup><xref ref-type="bibr" rid="R2">2</xref><xref ref-type="bibr" rid="R3">–</xref><xref ref-type="bibr" rid="R5">5</xref></sup> Several cases of <italic>EHMT1</italic>-negative patients exhibiting the KS phenotype with mutations in 4 functionally similar epigenetic regulator genes (<italic>MBD5, MLL3, SMARCB1,</italic> and <italic>NR113</italic>) have been reported.<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref></sup>
<italic>EHMT1</italic> knockout mice also display impaired fear conditioning, indicative of learning and memory defects.<sup><xref ref-type="bibr" rid="R6">6</xref></sup> Similar studies have also been demonstrated in <italic>Drosophila</italic>.<sup><xref ref-type="bibr" rid="R5">5</xref></sup></p><p>Neuroimaging in patients with KS has not been consistently reported (table e-1 at <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000058">Neurology.org/ng</ext-link>). In many cases, normal MRIs were noted, although white matter (WM) changes and corpus callosum hypoplasia have been observed. Of interest, differentiation in oligodendrocyte development, an important process in the myelination of the CNS, has been shown to be affected by epigenetic regulation.<sup><xref ref-type="bibr" rid="R7">7</xref></sup></p><sec disp-level="2" id="s1-1"><title>Case report.</title><sec id="s1-1-1"><title>Presentation.</title><p>The patient initially presented as a 20-month-old ambidextrous boy with global developmental delay and facial dysmorphic features, including midfacial hypoplasia, horizontal palpebral fissures, prominent lower lip, and upturned ear lobes, characteristic of KS. Pregnancy, perinatal, and family history were unremarkable. Developmental delay was first noticed at 8 months, and the patient did not sit independently until 12 months of age. He was found to have severely impaired gross motor skills with moderate impairment in language. Examination revealed 75th percentile for weight, length, and head circumference. Cranium was abnormally shaped with right plagiocephaly. There were no focal anomalies on his neurologic examination.</p></sec><sec id="s1-1-2"><title>Follow-up.</title><p>By age 4 he could walk independently and sit on a tricycle. He was diagnosed with severe expressive speech delay and moderate receptive speech delay. Most of his communication came from signing and use of a Picture Exchange Communication System; he nonspecifically used the single word “mom.” He was very social with family and strangers alike. At age 7, he remained nonverbal.</p></sec><sec id="s1-1-3"><title>Investigations.</title><p>Using chromosomal microarray analysis, a 60,654-bp interstitial deletion spanning the distal long arm of chromosome 9 (9q34.3) from nucleotide position 139,816,260 to 139,876,914 (NCBI36/Hg18) was reported. Parental testing was negative, indicative of a de novo lesion. Consent for publication was obtained from the parents. This deletion led to loss of the last 9 exons (i.e., exons 20–28) of the <italic>EHMT1</italic> gene, affecting the pre-SET and SET domains, as well as the last repeats of the ankyrin motif (<xref ref-type="fig" rid="F1">figure, A</xref>). At 2 years, he had a brain MRI showing several T2 and fluid-attenuated inversion recovery hyperintensities in periventricular WM, bilaterally seen at various levels (<xref ref-type="fig" rid="F1">figure, B–E</xref>). Of interest, a repeat MRI of the brain at age 6 showed marked reduction or resolution of the previously identified WM abnormalities (<xref ref-type="fig" rid="F1">figure, F–I</xref>).</p><fig id="F1" position="float"><label>Figure</label><caption><title>Genetic deletion and MRI changes with <italic>EHMT1</italic> deletion</title><p>(A) <italic>EHMT1</italic> gene is represented (top) with its numbered exon regions (merged into Hg19 assembly). The EHMT1 protein includes 3 important functional domains: (1) ankyrin domain, (2) pre-SET domain, and (3) SET domain. Previously published deletions restricted to the functional domains are identified. (B–I) MRI of the brain of the patient described in this study. (B–D) Axial MRI fluid-attenuated inversion recovery images of the brain with arrows pointing toward anomalies noted at 2 years of age. (E) Coronal T2 image of the brain also showing anomalous white matter signal. (F–I) Similar sequences on MRI at 6 years of age showed marked reduction of the hyperintense T2 signal in the region of the white matter anomalies previously seen at 2 years of age.</p></caption><graphic xlink:href="NG2015001511FF1"></graphic></fig></sec></sec><sec disp-level="2" id="s1-2"><title>Discussion.</title><p>KS is a recognized cause of syndromic ID associated with <italic>EHMT1</italic> mutations. WM abnormalities have been reported previously on MRIs of patients with KS. Available neuroimaging data (table e-1) suggest that WM lesions are frequent brain abnormalities observed in KS. However, serial imaging has not been reported systematically for most of these patients.</p><p>There is growing evidence in recent years for the role of epigenetic temporal changes that affect structural brain changes in relation to neurodevelopmental phenotypes (i.e., Rett syndrome, autism spectrum disorder). The SET domain is responsible for histone methylation in humans,<sup><xref ref-type="bibr" rid="R8">8</xref></sup> and conditional ablation of Ehmt1 in postnatal mouse forebrain neurons causes a reduction in euchromatic H3K9 methylation and upregulation of neuronal and non-neuronal genes. Transition from electrically active to myelinating oligodendrocytes requires H3K9 methylation. It remains unclear whether this is EHMT1 dependent. The ankyrin domain, a second motif deleted in our patient, may also be associated with myelination, in addition to its role in proliferation and migration.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> Some isoforms of ankyrin localize to the junction between myelinated sheets.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> Our study illustrates that in addition to its role in neuronal proliferation, EHMT1 may regulate myelination development and suggests a value in serial imaging in patients with KS.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="PMC_1">
<caption>
<title>Data Supplement</title>
</caption>
<media mime-subtype="html" mimetype="text" xlink:href="supp_2_2_e58__index.html"></media>
<media mime-subtype="msword" mimetype="application" xlink:href="supp_2.2.e58_Supplemental_Data.docx" xlink:role="associated-file"></media>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supplementary-material">
<p>Supplemental data at <ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000058">Neurology.org/ng</ext-link></p>
</fn>
<fn fn-type="other">
<p>Author contributions: Xu He: acquisition of data, analysis, manuscript preparation. Oana Caluseriu: data analysis, supervision, manuscript preparation. Ratika Srivastava: acquisition of data, manuscript preparation. Anne Marie Denny: revision of the manuscript for important intellectual content. Francois V. Bolduc: acquisition of data, analysis, manuscript preparation, supervision.</p>
</fn>
<fn fn-type="financial-disclosure">
<p><italic>Study funding: No targeted funding reported</italic>.</p>
</fn>
<fn fn-type="financial-disclosure">
<p><italic>Disclosure: The authors report no disclosures</italic>. <italic>Go to</italic>
<ext-link ext-link-type="doi" xlink:href="10.1212/NXG.0000000000000058"><italic>Neurology.org/ng</italic></ext-link>
<italic>for full disclosure forms. The Article Processing Charge was paid by the authors.</italic></p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Amiel</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome</article-title>. <source/>Am J Hum Genet
<year>2006</year>;<volume>79</volume>:<fpage>370</fpage>–<lpage>377</lpage>.<pub-id pub-id-type="pmid">16826528</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>Vulto-van Silfhout</surname><given-names>AT</given-names></name><name><surname>Nillesen</surname><given-names>WM</given-names></name><etal></etal></person-group>
<article-title>Update on Kleefstra syndrome</article-title>. <source/>Mol Syndromol
<year>2012</year>;<volume>2</volume>:<fpage>202</fpage>–<lpage>212</lpage>.<pub-id pub-id-type="pmid">22670141</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>Kramer</surname><given-names>JM</given-names></name><name><surname>Neveling</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability</article-title>. <source/>Am J Hum Genet
<year>2012</year>;<volume>91</volume>:<fpage>73</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">22726846</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balemans</surname><given-names>MC</given-names></name><name><surname>Kasri</surname><given-names>NN</given-names></name><name><surname>Kopanitsa</surname><given-names>MV</given-names></name><etal></etal></person-group>
<article-title>Hippocampal dysfunction in the Euchromatin histone methyltransferase 1 heterozygous knockout mouse model for Kleefstra syndrome</article-title>. <source/>Hum Mol Genet
<year>2013</year>;<volume>22</volume>:<fpage>852</fpage>–<lpage>866</lpage>.<pub-id pub-id-type="pmid">23175442</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>JM</given-names></name><name><surname>Kochinke</surname><given-names>K</given-names></name><name><surname>Oortveld</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>Epigenetic regulation of learning and memory by Drosophila EHMT/G9a</article-title>. <source/>PLoS Biol
<year>2011</year>;<volume>9</volume>:<fpage>e1000569</fpage>.<pub-id pub-id-type="pmid">21245904</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>A</given-names></name><name><surname>Sampath</surname><given-names>SC</given-names></name><name><surname>Intrator</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex</article-title>. <source/>Neuron
<year>2009</year>;<volume>64</volume>:<fpage>678</fpage>–<lpage>691</lpage>.<pub-id pub-id-type="pmid">20005824</pub-id></mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Magri</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Chromatin landscape defined by repressive histone methylation during oligodendrocyte differentiation</article-title>. <source/>J Neurosci
<year>2015</year>;<volume>35</volume>:<fpage>352</fpage>–<lpage>365</lpage>.<pub-id pub-id-type="pmid">25568127</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Jing</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>JR</given-names></name><etal></etal></person-group>
<article-title>Structure and catalytic mechanism of the human histone methyltransferase SET7/9</article-title>. <source/>Nature
<year>2003</year>;<volume>421</volume>:<fpage>652</fpage>–<lpage>656</lpage>.<pub-id pub-id-type="pmid">12540855</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>D</given-names></name><name><surname>Voronova</surname><given-names>A</given-names></name><name><surname>Zander</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>Ankrd11 is a chromatin regulator involved in autism that is essential for neural development</article-title>. <source/>Dev Cell
<year>2015</year>;<volume>32</volume>:<fpage>31</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">25556659</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kordeli</surname><given-names>E</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Trapp</surname><given-names>B</given-names></name><name><surname>Bennett</surname><given-names>V</given-names></name></person-group>
<article-title>An isoform of ankyrin is localized at nodes of Ranvier in myelinated axons of central and peripheral nerves</article-title>. <source/>J Cell Biol
<year>1990</year>;<volume>110</volume>:<fpage>1341</fpage>–<lpage>1352</lpage>.<pub-id pub-id-type="pmid">2139035</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>van Zelst-Stams</surname><given-names>WA</given-names></name><name><surname>Nillesen</surname><given-names>WM</given-names></name><etal></etal></person-group>
<article-title>Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype</article-title>. <source/>J Med Genet
<year>2009</year>;<volume>46</volume>:<fpage>598</fpage>–<lpage>606</lpage>.<pub-id pub-id-type="pmid">19264732</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>